Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial by Pignata, Sandro, MD, Lorusso, Domenica, MD, Joly, Florence, MD, Gallo, Ciro, Prof, Colombo, Nicoletta, Prof, Sessa, Cristiana, Prof, Bamias, Aristotelis, Prof, Salutari, Vanda, MD, Selle, Frédèric, MD, Frezzini, Simona, MD, De Giorgi, Ugo, MD, Pautier, Patricia, MD, Bologna, Alessandra, MD, Orditura, Michele, Prof, Dubot, Coraline, MD, Gadducci, Angiolo, Prof, Mammoliti, Serafina, MD, Ray-Coquard, Isabelle, Prof, Zafarana, Elena, MD, Breda, Enrico, MD, Favier, Laure, MD, Ardizzoia, Antonio, MD, Cinieri, Saverio, Prof, Largillier, Rémy, MD, Sambataro, Daniela, MD, Guardiola, Emmanuel, MD, Lauria, Rossella, MD, Pisano, Carmela, MD, Raspagliesi, Francesco, MD, Scambia, Giovanni, MD, Daniele, Gennaro, MD, Perrone, Francesco, MD

Get full text

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with meta... by Cremolini, Chiara, MD, Antoniotti, Carlotta, MD, Rossini, Daniele, MD, Lonardi, Sara, MD, Loupakis, Fotios, MD, Pietrantonio, Filippo, MD, Bordonaro, Roberto, MD, Latiano, Tiziana Pia, MD, Tamburini, Emiliano, MD, Santini, Daniele, Prof, Passardi, Alessandro, MD, Marmorino, Federica, MD, Grande, Roberta, MD, Aprile, Giuseppe, MD, Zaniboni, Alberto, MD, Murgioni, Sabina, MD, Granetto, Cristina, MD, Buonadonna, Angela, MD, Moretto, Roberto, MD, Corallo, Salvatore, MD, Cordio, Stefano, MD, Antonuzzo, Lorenzo, MD, Tomasello, Gianluca, MD, Masi, Gianluca, Prof, Ronzoni, Monica, MD, Di Donato, Samantha, MD, Carlomagno, Chiara, Prof, Clavarezza, Matteo, MD, Ritorto, Giuliana, MD, Mambrini, Andrea, MD, Roselli, Mario, Prof, Cupini, Samanta, MD, Mammoliti, Serafina, MD, Fenocchio, Elisabetta, MD, Corgna, Enrichetta, MD, Zagonel, Vittorina, MD, Fontanini, Gabriella, Prof, Ugolini, Clara, MD, Boni, Luca, MD, Falcone, Alfredo, Prof

Get full text

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial by Garassino, Marina Chiara, MD, Martelli, Olga, MD, Broggini, Massimo, PhD, Farina, Gabriella, MD, Veronese, Silvio, PhD, Rulli, Eliana, PhD, Bianchi, Filippo, MD, Bettini, Anna, MD, Longo, Flavia, MD, Moscetti, Luca, MD, Tomirotti, Maurizio, MD, Marabese, Mirko, PhD, Ganzinelli, Monica, PhD, Lauricella, Calogero, PhD, Labianca, Roberto, MD, Floriani, Irene, PhD, Giaccone, Giuseppe, MD, Torri, Valter, MD, Scanni, Alberto, MD, Marsoni, Silvia, MD

Get full text

Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial by Colombo, Nicoletta, Prof, Biagioli, Elena, MSc, Harano, Kenichi, MD, Galli, Francesca, MSc, Hudson, Emma, MD, Antill, Yoland, MD, Choi, Chel Hun, MD, Rabaglio, Manuela, MD, Marmé, Frederic, MD, Marth, Christian, MD, Parma, Gabriella, MD, Fariñas-Madrid, Lorena, MD, Nishio, Shin, MD, Allan, Karen, BSc, Lee, Yeh Chen, MD, Piovano, Elisa, MD, Pardo, Beatriz, MD, Nakagawa, Satoshi, MD, McQueen, John, MD, Zamagni, Claudio, MD, Manso, Luis, MD, Takehara, Kazuhiro, MD, Tasca, Giulia, MD, Ferrero, Annamaria, MD, Tognon, Germana, MD, Lissoni, Andrea Alberto, MD, Petrella, Mariacristina, MD, Laudani, Maria Elena, MD, Rulli, Eliana, PhD, Uggeri, Sara, MSc, Barretina Ginesta, M Pilar, MD

Get full text